Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016
Early eradication of pseudomonas aeruginosa (PA) in cystic fibrosis patients (CF): Which is the best treatment? Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013
LATE-BREAKING ABSTRACT: Is there a relationship between use of inhaled antibiotics and prevalence of fungal isolates in the respiratory secretions of people with cystic fibrosis? A retrospective data analysis Source: International Congress 2015 – Cystic fibrosis: assessment and treatment Year: 2015
Lung deposition of inhaled colistimethate sodium in cystic fibrosis patients Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014
The use of telehealth system in improving adherence to nebulised treatment in children with cystic fibrosis: Benefits and pitfalls Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014
The oral AntibioticS approprIateness score (OASIS) – A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF) Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013
Inhaled therapy in cystic fibrosis: agents, devices and regimens Source: Breathe 2015; 11:110-118 Year: 2015
Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016
Inhaled antibiotics in cystic fibrosis: what we should do and what we still do not know Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016
Inhaled antimicrobials Source: ERS webinar 2020: Inhaled antimicrobials Year: 2020
Patients with no cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa : Role of inhaled colistin Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014
Lung transplantation for Non- Cystic fibrosis bronchiectasis: A single centre retrospective analysis of 34 patients Source: International Congress 2015 – Outcomes of lung transplantation Year: 2015
Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016
Safety, tolerability and efficacy of intravenous aminophylline in adult patients with pulmonary exacerbations of cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014
Side effects of inhaled tobramycin in patients with Cystic Fibrosis Source: Eur Respir J 2002; 20: Suppl. 38, 526s Year: 2002
Prescription of Inhaled corticosteroid in non-cystic fibrosis bronchiectasis:a solution or a problem Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease Year: 2020
Inhaled antibiotics in non-cystic fibrosis bronchiectasis: better than oral antibiotics? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016
Inhaled mannitol in cystic fibrosis: clinical experience in Verona CF centre Source: Virtual Congress 2020 – New insights into respiratory physiotherapy Year: 2020
Lung Clearance Index (LCI) and FEV1 on the evaluation of the effect of tobramycin solution for inhalation (TIS) among patients with cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment Year: 2014